Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects
Sponsor: Shine-On Biomedical Co., Ltd.
Summary
The investigational drug, SOB100, is an HLA-G targeted exosome equipped with a nanobody namely anti-HLA-G VHH on the exosome membrane. This is a Phase I dose escalation study to exam the tolerability, safety, and pharmacokinetics in healthy subjects.
Official title: An Open-label and Dose-escalation Phase I Clinical Study to Evaluate the Tolerability, Safety, and Pharmacokinetics of HLA-G-targeted Exosome (SOB100) in Healthy Subjects
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
15
Start Date
2025-12-01
Completion Date
2027-03
Last Updated
2026-01-26
Healthy Volunteers
Yes
Conditions
Interventions
SOB100
Drug: SOB100 Participants will receive SOB100 and evaluate the safety and tolerability of SOB100 during the dose escalation phase.
Locations (1)
Parexel International - Baltimore Early Phase Clinical Unit
Baltimore, Maryland, United States